文献速递骨质疏松与代谢性骨病创伤骨科

长期口服糖皮质激素停药后骨折风险快速下降:基于日本全国健康保险索赔数据库的回顾性队列研究

Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan.
PubMed 文献 · Osteoporos Int · 2024-10-21

该回顾性队列研究利用日本全国健康保险索赔数据库,纳入2012—2019年起始口服糖皮质激素且年龄≥50岁的患者,比较停药组、续药组与参照组的髋部及临床椎体骨折风险。调整后风险比显示,停药后最初90天内骨折发生率显著低于续药组并持续至360天(男性髋部骨折除外),但停药组髋部骨折风险在停药后720天内仍显著高于参照组。

要点

  • 停药后最初90天骨折发生率显著低于续药组,并持续至360天,但男性髋部骨折除外。
  • 停药组髋部骨折风险在停药后720天内仍显著高于参照组。
  • 结论认为骨折风险在停药后第一年快速下降,但增加的风险可持续至停药后两年。

核心结论

  • 骨折风险在糖皮质激素停药后第一年快速下降,但增加的风险可持续至停药后两年,需保持警惕。

研究设计与样本

  • 回顾性队列研究,使用日本全国健康保险索赔数据库(NDBJ),纳入2012—2019年起始糖皮质激素治疗且年龄≥50岁的患者。
  • 糖皮质激素暴露组定义为初始90天内接受≥5 mg/天(泼尼松龙或等效剂量,PSL)且≥72天者;参照组定义为接受<5 mg PSL/天且<30天者。
  • 糖皮质激素治疗90天后停药者归为停药组,其余归为续药组;追踪髋部及临床椎体骨折发生率至990天,采用倾向评分逆概率加权调整的风险比(HR)评估停药后骨折风险。

主要发现

  • 女性中,停药组52,179例、续药组91,969例、参照组43,138例;男性中,相应组分别为57,560例、93,736例、33,696例。
  • 调整后HR显示,停药后最初90天内停药组骨折发生率显著低于续药组,并持续显著至360天,但男性髋部骨折除外。
  • 停药组髋部骨折风险在停药后720天内仍显著高于参照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Increased fracture risk due to oral glucocorticoids (GCs) rapidly decreases with GC discontinuation. However, evidence for this is limited. We found that fracture risk decreased rapidly in the first year after GC discontinuation, while hip fracture risk remained higher than reference levels for about two years after GC discontinuation. PURPOSE: We investigated changes in fracture risk following discontinuation of long-term oral glucocorticoids (GCs) using Japan's nationwide health insurance claims database (NDBJ). METHODS: We identified patients aged ≥ 50 years who initiated GC therapy in 2012-2019. Those receiving ≥ 5 mg (prednisolone or equivalent, PSL)/day for ≥ 72 days in the initial 90 days of GC therapy were classified as the GC-exposure group, and those receiving < 5 mg PSL/day for < 30 days were classified as the reference group. Patients discontinuing GC after 90 days of GC therapy were classified as the GC-discontinuation group; all others were classified as the GC-continuation group. We tracked the incidence rates of hip and clinical vertebral fractures for up to 990 days, and assessed fracture risk after GC discontinuation by hazard ratios (HR) adjusted by inverse probability weighting using propensity scores for GC discontinuation. RESULTS: There was a total of 52,179 GC-discontinuation, 91,969 GC-continuation, and 43,138 reference group women, and 57,560, 93,736, and 33,696 men in the corresponding groups, respectively. According to adjusted HRs, incidence rates of fractures were significantly lower in the GC-discontinuation group than in the GC-continuation group in the initial 90 days after GC discontinuation and remained significant for 360 days, except for hip fracture in men. HRs for hip fractures remained significantly higher in the GC-discontinuation group compared to the reference group for 720 days post-discontinuation. CONCLUSION: Fracture risk declines rapidly in the first year after GC discontinuation, but vigilance is necessary as the increased risk persists for two years post-discontinuation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Iki M, Fujimori K, Okimoto N, et al. Rapid reduction in fracture risk after the discontinuation of long-term oral glucocorticoid therapy: a retrospective cohort study using a nationwide health insurance claims database in Japan. Osteoporos Int. 2024. PMID: 39432088. doi:10.1007/s00198-024-07284-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。